Claes Henning New Scientific Advisor to IDL Biotech AB
IDL Biotech continues to strengthen its scientific knowledge by appointing an additional experienced scientific advisor.
Professor Claes Henning is Associate Professor in Clinical Bacteriology from Umeå University. He started his career at The National Bacteriology Laboratory (SBL) in 1962, and has since been devoted to clinical microbiology and infectious diseases. Professor Henning has worked with clinical trials of antibiotics and diagnostics as well as quality improvement in laboratory operations. Professor Henning has more than 100 publications.
Beyond working at several Swedish hospitals, Claes also worked in United Arab Emirates (UAE) for over fifteen years, including Ministry of Health, General Health Services, Health Authority Abu Dhabi and Dubai Healthcare Authority.
Professor Hennings extended experience will help IDL Biotech to ensure that our current and future research is based on appropriate and validated methodologies. His appointment is a testimony to the importance we place on the scientific validity and robustness of our products.
"We are very excited to have Professor Henning as a part of our team. His extensive experience and knowledge within bacteriology will help IDL achieve its scientific goals, says Charlotte Berg, CEO at IDL Biotech AB.
“We are delighted to include both Professor Henning and Professor Abrahamsson in our team. Clearly their deep scientific expertise as well as their contacts and overall knowledge base will be extremely helpful”, says Hans Örström, Chairman of the Board.
For further information please contact:
IDL Biotech AB (publ)
Charlotte Berg, CEO
+46 8 799 67 50
IDL Biotech AB (publ) är ett publikt svenskt bioteknikbolag, specialiserat på in vitro diagnostik inom onkologi och bakteriologi. Bolaget utvecklar, producerar och marknadsför unika och kostnadseffektiva produkter för medicinskt angelägna indikationer. IDL Biotech AB (publ) har ett etablerat internationellt distributörsnätverk. Bolagets aktier (IDL B) är noterade på Aktietorget.